Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone
Autore:
Ganguli, R; Brar, JS; Ayrton, Z;
Indirizzi:
Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15213 USA Univ Pittsburgh Pittsburgh PA USA 15213 sychiat, Pittsburgh, PA 15213 USA
Titolo Testata:
SCHIZOPHRENIA RESEARCH
fascicolo: 3, volume: 49, anno: 2001,
pagine: 261 - 267
SICI:
0920-9964(20010430)49:3<261:WGO4MI>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
SIDE-EFFECT PROFILES; HALOPERIDOL; CLOZAPINE; MEDICATION; TRIAL;
Keywords:
atypical antipsychotic; body mass index; olanzapine; risperidone; weight gain;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Life Sciences
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Ganguli, R Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15213 USA Univ Pittsburgh Pittsburgh PA USA 15213 ttsburgh, PA 15213 USA
Citazione:
R. Ganguli et al., "Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone", SCHIZOPHR R, 49(3), 2001, pp. 261-267

Abstract

Weight gain frequently accompanies treatment with antipsychotics. In orderto determine whether newer antipsychotic agents differ from each other with respect to weight gain, we compared two cohorts of patients with DSM-IV schizophrenia who had newly started treatment with either risperidone or olanzapine. After obtaining informed consent, data regarding body weight and height were culled from existing medical records of 100 patients (50 patients in each treatment group). Baseline body weight, close to the time of starting the new medication, and body mass index [BMI = weight (kg)/height (m) squared] were compared to the body weight and BMI following 4 months of treatment. There was no significant change in mean body weight or BMI in the group treated with risperidone (baseline weight = 83.1 kg +/- 20.5, follow-up = 82.8 kg +/- 19.9; matched pair t = 0.66, P = n.s.; baseline BMI = 29.6 /- 9.4, follow-up = 29.5 +/- 9.1; matched pair t = 0.79, P = n.s.). However, in the group treated with olanzapine, there was a significant increase in both mean body weight and BMI (baseline weight = 84.9 kg +/- 25.0, follow-up = 87.1 kg +/- 25.1; matched pair t = 4.62, P < 0.001; baseline BMI = 29.5 +/- 7.4, follow-up = 30.3 +/- 7.5; matched pair t = 4.43, P < 0.001). Inthis naturalistic study, treatment with olanzapine was associated with a mean weight gain of about 2 kg from baseline, in patients with schizophrenia, while treatment with risperidone was associated with no mean weight change. (C) 2001 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/20 alle ore 16:53:05